205 related articles for article (PubMed ID: 36151773)
1. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Metts JL; Trucco M; Weiser DA; Thompson P; Sandler E; Smith T; Crimella J; Sansil S; Thapa R; Fridley BL; Llosa N; Badgett T; Gorlick R; Reed D; Gill J
Cancer Med; 2023 Feb; 12(4):4270-4281. PubMed ID: 36151773
[TBL] [Abstract][Full Text] [Related]
2. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
[TBL] [Abstract][Full Text] [Related]
3. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S
Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors.
Metts J; Harrington B; Salman E; Bradfield SM; Flanary J; Mosha M; Amankwah E; Stapleton S
Childs Nerv Syst; 2022 May; 38(5):919-928. PubMed ID: 35260913
[TBL] [Abstract][Full Text] [Related]
6. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
Defachelles AS; Bogart E; Casanova M; Merks JHM; Bisogno G; Calareso G; Gallego Melcon S; Gatz SA; Le Deley MC; McHugh K; Probst A; Rocourt N; van Rijn RR; Wheatley K; Minard-Colin V; Chisholm JC
J Clin Oncol; 2021 Sep; 39(27):2979-2990. PubMed ID: 34343032
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Wagner LM; Perentesis JP; Reid JM; Ames MM; Safgren SL; Nelson MD; Ingle AM; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2010 Apr; 54(4):538-45. PubMed ID: 20049936
[TBL] [Abstract][Full Text] [Related]
8. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
Xu J; Xie L; Sun X; Liu K; Liang X; Cai Z; Tang X; Guo W
Clin Cancer Res; 2023 Mar; 29(6):1040-1046. PubMed ID: 36622702
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
Wagner L; Turpin B; Nagarajan R; Weiss B; Cripe T; Geller J
Pediatr Blood Cancer; 2013 Sep; 60(9):1447-51. PubMed ID: 23630159
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.
Venkatramani R; Malogolowkin M; Davidson TB; May W; Sposto R; Mascarenhas L
PLoS One; 2013; 8(7):e68416. PubMed ID: 23894304
[TBL] [Abstract][Full Text] [Related]
11. Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
Ju HY; Park M; Lee JA; Park HJ; Park SY; Kim JH; Kang HG; Yang HC; Park BK
Cancer Res Treat; 2022 Apr; 54(2):563-571. PubMed ID: 34126703
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
Mascarenhas L; Ogawa C; Laetsch TW; Weigel BJ; Bishop MW; Krystal J; Borinstein SC; Slotkin EK; Muscal JA; Hingorani P; Levy DE; Mo G; Shahir A; Wright J; DuBois SG
Cancer Med; 2021 Feb; 10(3):843-856. PubMed ID: 33474828
[TBL] [Abstract][Full Text] [Related]
14. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.
Raciborska A; Bilska K; Drabko K; Chaber R; Pogorzala M; Wyrobek E; Polczyńska K; Rogowska E; Rodriguez-Galindo C; Wozniak W
Pediatr Blood Cancer; 2013 Oct; 60(10):1621-5. PubMed ID: 23776128
[TBL] [Abstract][Full Text] [Related]
15. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
[TBL] [Abstract][Full Text] [Related]
16. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
McNall-Knapp RY; Williams CN; Reeves EN; Heideman RL; Meyer WH
Pediatr Blood Cancer; 2010 Jul; 54(7):909-15. PubMed ID: 20405511
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
Wagner LM; Crews KR; Iacono LC; Houghton PJ; Fuller CE; McCarville MB; Goldsby RE; Albritton K; Stewart CF; Santana VM
Clin Cancer Res; 2004 Feb; 10(3):840-8. PubMed ID: 14871959
[TBL] [Abstract][Full Text] [Related]
18. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.
Wang BC; Xiao BY; Lin GH
BMC Cancer; 2022 Mar; 22(1):349. PubMed ID: 35361149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
